Significantly increased levels of fatty acids are well documented in obesity and diabetes, and so reduced polyunsaturated fatty acids and fatty acyls with PEG-OB(Cys10, Cys13) treatment in DIO animals suggests that obestatin has the potential to protect against lipid dysregulation under these conditions (Lopaschuk et al. 2010). Here, GHRL is linked to diabetes mellitus.